Thyroid GuidePx® predicts how a person’s cancer will behave. The test guides health care teams in making important decisions on the clinical management of papillary thyroid cancer.
The incidence of papillary thyroid cancer is increasing by about 6% per year. Papillary thyroid cancer is not usually life-threatening, but recurrence after treatment can significantly affect the quality of life. Identifying high-risk individuals helps to direct appropriately aggressive treatment to those who need it. At the same time, confidently identifying individuals with a very low risk of recurrence will help select when more conservative treatment can be offered.